(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that “drug companies have
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on litigation, filed in the U.S. District Court of the District of Columbia, regarding the Trump administration’s final rule Transparency in Coverage: To avoid higher prescription drug costs for
JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare
Biosimilars play an important role in lowering net costs.
New report from the Congressional Budget Office highlights the value of PBMs in keeping net drug costs low for payers and patients.
Dr. Lawton Burns Says PBMs are Unfairly Blamed for High Drug Prices, Should Look At Big Drug Companies In case you missed it, Lawton R. Burns, PhD, professor of health care management at the Wharton School of the University of
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement regarding a white paper released today by the American Diabetes Association on insulin prices: “The American Diabetes Association’s new white paper on insulin prices confirms that drugmakers set, and
©2024 PCMA. All Rights Reserved.
